Sun Pharmaceutical Industries Ltd said today that the US Food and Drug Administration (FDA) had listed the Indian drugmaker's facility in the western state of Gujarat under an import alert.
The import alert means all future shipments of products made at Halol can be refused admission to the US market until the facility becomes compliant with the FDA's Current Good Manufacturing Practice standards, the company said.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
